Clinical Trials Browser

INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Lenalidomide × Clear all

Lymphoma, Large B-Cell, Diffuse

NCT04542824 2026-03-03

EPCORE™ NHL-3

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-03-03

EPCORE DLBCL-3

Phase 2 Active not recruiting

111 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-03-03

EPCORE DLBCL-4

Phase 3 Recruiting

360 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04903197 2026-01-22

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05222555 2026-01-16

MINDway

Phase 1/2 Active not recruiting

53 enrolled 14 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04661007 2025-12-18

J-MIND

Phase 1/2 Active not recruiting

72 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

150 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05429268 2025-12-10

firmMIND

Phase 3 Active not recruiting

82 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04824092 2025-09-08

frontMIND

Phase 3 Active not recruiting

899 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04436107 2025-05-23

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

66 enrolled 52 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02285062 2023-06-22

ROBUST

Phase 3 Completed

570 enrolled 27 charts

Lymphoid

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT02077166 2022-02-04

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 22 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00474188 2009-09-02

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Terminated

26 enrolled 5 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

ECHELON-3

EPCORE™ NHL-3

EPCORE™ NHL-2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

EPCORE DLBCL-3

EPCORE DLBCL-4

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

MINDway

J-MIND

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

firmMIND

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

frontMIND

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

L-MIND

ROBUST

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MK-3475-013

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma